Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Osteoporosis 9Breast Neoplasms 6Bone Diseases, Metabolic 5Prostatic Neoplasms 4Triple Negative Breast Neoplasms 1Prostatic Hyperplasia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteoporosis, Postmenopausal 1Lymphoma 1Lung Neoplasms 1Leukemia 1Dwarfism, Pituitary 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1

Interventions

Dutasteride 3acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 2proxalutamide 1polyphenon E 1mirabegron 1TroVax 1Transurethral Resection of Prostate 1Transurethral Resection of Bladder 1Therapeutics 1Tamsulosin 1Standard of Care 1Risedronic Acid 1Radiotherapy 1Psychiatric Rehabilitation 1Prostatectomy 1Papaverine 1Oxygen 1Nitrous Oxide 1Needles 1Microspheres 1Lycopene 1Levofloxacin 1Finasteride 1Electroacupuncture 1Doxazosin 1Docetaxel 1Diclofenac 1Dexmedetomidine 1Cystoscopy 1Celecoxib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Prostatic Hyperplasia × Risedronic Acid × Clear all
NCT00426777 2012-02-03

Efficacy Study of Risedronate to Prevent Cancer Treatment-Induced Bone Loss in Prostate Cancer

CMX Research

Phase 3 Completed
160 enrolled
Genitourinary

Prostatic Hyperplasia, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡